Jump to start of content

Technical Support for those taking the Knowledge Check-In at home/in office Expand/Collapse the ABIM alert.

Technical assistance on the day of your Knowledge Check-In assessment is available by chatting with a Pearson VUE agent. We are here to help! You may also call 800-606-0259 to reach an ABIM Customer Relationship Advocate, in the event you are unable to connect to a Pearson VUE agent.

Coronavirus Updates Expand/Collapse the ABIM alert.

At ABIM we are actively monitoring the ongoing spread of coronavirus (COVID-19) and will post regular updates about any changes to scheduled assessments.
Scheduled for an assessment this year? ABIM is working with Pearson VUE to ensure your safety throughout your exam day. Learn more about what to expect at test centers.
Please follow the United States Centers for Disease Control and Prevention (CDC) for the most up-to-date information on the virus.

Breadcrumb trail:

Endocrinology, Diabetes, and Metabolism Board Exam Committee

Expand All | Collapse All

Paul W. Ladenson, MD, Chair

Paul W. Ladenson, MD, ChairDr. Ladenson, a board certified internist and endocrinologist, is the John Eager Howard Professor of Endocrinology and Metabolism and Director of the Division of Endocrinology, Diabetes, & Metabolism at the Johns Hopkins Medical Institutions, where he is Professor of Medicine, Pathology, Oncology, and Radiology and Radiological Sciences, as well as a University Distinguished Professor. He is also Professor of International Health at the Johns Hopkins Bloomberg School of Public Health. His academic career has been as a clinical investigator and educator in thyroidology, and his principal research interests have been thyroid hormone actions on the heart, thyroid cancer, thyroid hormone analogs and health economic analyses related to clinical endocrinology.

Dr. Ladenson serves as a member of the American Board of Internal Medicine (ABIM) Endocrinology, Diabetes, and Metabolism Board as well as Chair of the ABIM Endocrinology, Diabetes, and Metabolism Board Exam Committee. He is past Editor-in-Chief of the Journal of Clinical Endocrinology & Metabolism and has served in the past as President of the Association of Program Directors in Endocrinology and Metabolism, the Association of Subspecialty Professors and the American Thyroid Association.

Dr. Ladenson graduated summa cum laude from Dartmouth College with a degree in English literature, from Oxford University with a degree in physiology, and from Harvard Medical School (Alpha Omega Alpha). He trained as a resident in internal medicine and as a clinical and research fellow in endocrinology at Massachusetts General Hospital.

As of July 2019, Dr. Ladenson reported the external relationships:

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, receiving compensation for travel expenses and honoraria:

  • Veracyte, providing advice regarding clinical and health-economic research related to molecular genetic testing for differential diagnosis of thyroid nodules, receiving compensation for travel expenses and honoraria.
  • Viking Therapeutics, providing advice regarding preclinical and clinical research related to applications of thyromimetic compounds to metabolic disorders, receiving honoraria.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • Veracyte, for giving lectures to the Endocrine Society national and regional chapters.

Shehzad S. Basaria, MD

Shehzad S. Basaria, MDDr. Basaria is a Reproductive Endocrinologist and the Medical Director of the Section of Men's Health, Aging and Metabolism at the Brigham and Women's Hospital, Harvard Medical School. He is board certified in Endocrinology, Diabetes, and Metabolism.

Dr. Basaria is a clinical investigator in the field of male reproductive endocrinology. His research interests include the role of testosterone in pain perception, age-related androgen deficiency and cardiometabolic consequences of androgen deprivation therapy in men with prostate cancer. Dr. Basaria also provides clinical care to patients with male reproductive disorders. Additionally, he is a mentor to junior faculty and endocrine fellows pursuing their careers in reproductive endocrinology.

Dr. Basaria is a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board Exam Committee. He is the Associate Editor of the Journal of Gerontology Medical Sciences, and also serves on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and Endocrine Practice. Previously, Dr. Basaria led the section on Male Reproduction on the Self-Assessment Committee of the Endocrine Society. He was also previously involved in developing the Endocrine Society's Male Androgen Deficiency Performance Improvement Module, which practicing endocrinologists utilize towards their Maintenance of Certification. Dr. Basaria serves as a member of the National Institute of Child Health and Development's Special Emphasis Panel on Male Contraception.

Dr. Basaria received his medical degree from the Aga Khan University in Karachi, Pakistan. He completed house staff training at the University of Texas Health Science Center at Houston and his endocrine fellowship at the Johns Hopkins University School of Medicine.

As of August 2019, Dr. Basaria reported no external relationships.

Daniel H. Bessesen, MD

Daniel H. Bessesen, MDDr. Bessesen is Professor of Medicine at the University of Colorado, School of Medicine (UCSOM) and Chief of Endocrinology at Denver Health Medical Center. He is also the Fellowship Program Director for Fellowship Training in Endocrinology, Metabolism and Diabetes at the UCSOM and Associate Director of the Anschutz Health & Wellness Center. He is board certified in Internal Medicine and Endocrinology, Diabetes and Metabolism.

Dr. Bessesen has conducted National Institutes of Health (NIH) and Patient-Centered Outcomes Research Institute funded research in dietary fat metabolism, body weight regulation and the clinical problem of obesity at the University of Colorado and Denver Health Medical Center for more than 25 years. He is a member of the American Board of Internal Medicine Endocrinology, Diabetes and Metabolism Board Exam Committee. He previously served on and chaired the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) C study section which evaluates grant applications for trainees and training programs in nutrition and gastroenterology. Dr. Bessesen also served on and chaired the NIH NIDDK Clinical and Integrative Diabetes and Obesity (CIDO) study section which reviews patient oriented research grant applications related to the prevention, pathogenesis and treatment of diabetes and/or obesity. He was a member of the Clinical Practice Guideline writing group for the Endocrine Society's guideline on the Pharmacological Management of Obesity and he served as the Chair of the Obesity Expert Panel for the Endocrine Society. He is a past recipient of the Roland L. Weinsier Award for Excellence in Medical/Dental Nutrition Education and the Physician Nutrition Specialist Award from the American Society for Nutrition.

Dr. Bessesen received a degree in chemistry from Colorado State University and his medical degree from UCSOM. He completed a residency and chief residency in internal medicine at the University of Colorado and a fellowship in endocrinology also at the University of Colorado.

As of July 2019, Dr. Bessesen reported the following external relationships:

Dr. Bessesen serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

    The Endocrine Society, Clinical Endocrine Update Committee Member, Speaker at an Endocrine Society meeting in India, receiving reimbursement for travel expenses.

Funding for clinical research, including salary support, from the following not-for-profit healthcare-related organization:

  • National Institutes of Health, for grants relating to obesity.

Cyrus V. Desouza, MD

Cyrus V. Desouza, MD Dr. Desouza is currently a Professor of Medicine and the Chief of Endocrinology at the University of Nebraska Medical Center in Omaha, NE. He is Board certified in Endocrinology, Diabetes & Metabolism and is currently participating in Maintenance of Certification. Dr. Desouza practices at the University of Nebraska Medical Center as well as the Omaha VA. He is also the Director of the Diabetes & Obesity Program at the Omaha VA.

He was the Associate Program Director of the Endocrinology fellowship and then the Program Director until 2011. His area of research interest is diabetes and its complications and more specifically cardiovascular complications and the effect of newer generation of diabetes medications on CVD outcomes. He does both basic research and clinical trials.

Dr. Desouza is a member of several professional organizations such as the Endocrine Society and American Diabetes Association and has served on several national committees. He is also a reviewer for DOD and NIH study sections and has published over 80 articles in multiple journals.

He received his medical MBBS degree from St John's Medical College in Bangalore, India. Dr. Desouza then did his Internal Medicine Residency at St Barnabas Hospital in NY. He completed his Endocrinology fellowship at Tulane University Medical Center, New Orleans, LA.

As of May 2020, Dr. Desouza reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the University of Nebraska Medical Center, from the following companies for trials relating to cardiovascular disease outcomes:

  • Kowa
  • Novo Nordisk

Attendance at investigators’ meetings, with compensation for travel expenses from the following companies:

  • Gilead
  • Novo Nordisk

Service on a research-related expert panel for the following companies, with honoraria:

  • AstraZeneca
  • Novo Nordisk

Dr. DeSouza serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • The Endocrine Society, SCEID & Advocacy Committee, without compensation.

Funding from not-for-profit healthcare-related organizations for clinical trial expenses, staff and salary support, paid to the University of Nebraska Medical Center, from the following companies:

  • Department of Defense, receiving funding for salary support, for a Defense Advanced Research Promects Agency grant.
  • National Institute of Diabetes and Digestive and Kidney Diseases, receiving funding for salary support for the study, Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study.

Matthew T. Drake, MD, PhD

Matthew T. Drake, MD, PhDDr. Drake is a Consultant in the Division of Endocrinology, Department of Medicine, and Associate Professor of Medicine at Mayo Clinic in Rochester, Minnesota. He is Board Certified in Endocrinology, Diabetes, and Metabolism.

Dr. Drake has received numerous awards, including the American Society for Bone and Mineral Research Young Investigator Award and the Mayo Clinic Department of Medicine New Investigator Award. He currently serves as Chair of the Mayo Clinic Metabolic Bone Disease Core Group. He also serves on the editorial boards of the Journal of Bone and Mineral Research; Bone; the Journal of Clinical Endocrinology and Metabolism; and Mayo Clinic Proceedings, and on the Scientific Advisory Board for the Soft Bones Foundation.

In his clinical practice, Dr. Drake is involved in providing care to patients with a variety of metabolic bone diseases. In addition, he performs translational research with areas of interest including understanding the mechanisms underlying age-associated bone loss and diabetes-associated skeletal fragility, as well as the basis by which monoclonal gammopathies induce bone loss and fractures.

Dr. Drake received his undergraduate degree in biology from Harvard College and completed his medical and doctoral degrees at Washington University in St. Louis, Missouri. His clinical training in internal medicine was completed at Duke University Medical Center in Durham, North Carolina. Dr. Drake completed his endocrinology fellowship training at the Mayo Clinic, where he subsequently joined the staff in 2007.

As of July 2019, Dr. Drake reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Mayo Clinic, from the following companies:

  • Clementia, for treatment of patients with a rare skeletal disorder with an investigational agent to limit new bone formation, with compensation for travel expenses, honoraria and salary support.
  • Regeneron, for treatment of patients with a rare skeletal disorder with an investigational agent to limit new bone formation, with compensation for travel expenses, honoraria and salary support.

Work as an author or editor for following companies, with compensation as listed:

  • UpToDate, receiving compensation for co-authorship for two chapters on osteomalacia.
  • Elsevier, receiving compensation for work as an editor for BONE.

Dr. Drake serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • The Endocrine Society, Member of Steering Committee for Annual Meeting, receiving reimbursement for travel expenses.

Pamela U. Freda, MD

Pamela U. Freda, MDDr. Freda is Professor of Medicine at Columbia University Irving Medical Center in New York. Dr. Freda is Clinical Director of Neuroendocrine Unit and co-director of the Pituitary Center at Columbia University Irving Medical Center. She is an Assistant Attending in Medicine at New York Presbyterian Hospital. Dr. Freda is board certified in Endocrinology, Diabetes and Metabolism (recertified 2005 and 2015), was board certified in Internal Medicine (recertified 2001) and is an active participant in the MOC program.

She joined the Faculty of the Division of Endocrinology, Department of Medicine, Columbia University of Physicians & Surgeons in 1994 and has remained on this faculty since this time. She conducts clinical research on pituitary diseases, teaches students, residents and fellows and practices Endocrinology with a focus on care of patients with pituitary tumors.

Dr. Freda served as Endocrine Society Self-Assessment Committee Member from 2010 – 2015, the Board of Directors of The Pituitary Society from 2010-2014 and as Chair of the Endocrine Society Clinical Guidelines Task Force on Pituitary Incidentaloma in 2011. At Columbia University Medical Center she has served on the GCRC Scientific Advisory Committee and currently serves as a Consultant for the Institutional Review Board and on the Clinical Trials Office Scientific Advisory Committee. Dr. Freda became a member of the Academy of Clinical Excellence, Columbia University Medical Center in 2016.

She received her undergraduate degree in History and Science from Harvard College and her medical degree from Columbia College of Physicians and Surgeons. She completed house staff training in Internal Medicine at The Presbyterian Hospital and her Endocrinology Fellowship at Columbia College of Physicians and Surgeons and The Presbyterian Hospital in New York.

As of May 2020, Dr. Freda reported no ongoingexternal relationships:

Daniel Rubin, MD

Daniel RubinDr. Rubin is an Associate Professor of Medicine in the Section of Endocrinology, Diabetes, and Metabolism at the Lewis Katz School of Medicine at Temple University and a Fellow of the American College of Endocrinology. His undergraduate degree is a Bachelor of Arts in Biology, magna cum laude, from Amherst College. He earned a Doctor of Medicine degree with research honors from the University of Florida College of Medicine. Board certified in both Internal Medicine and Endocrinology, Dr. Rubin completed Internal Medicine Residency at Thomas Jefferson University, Endocrinology Fellowship at Boston Medical Center, and earned a Master of Science in Epidemiology with a concentration in Biostatistics at the Boston University School of Public Health.

He also completed a research fellowship in the Boston University CREST program. In the Section of Endocrinology at Temple University, he serves as Deputy Section Chief and Director of Clinical Research. At Temple University Hospital, he is Chair of the Glycemic Control Taskforce. His research focuses on inpatient diabetes management and hospital readmissions among patients with diabetes. He is currently funded by the NIH and the American Diabetes Association.

As of September 2019, Dr. Rubin reported the following external relationships:

Work as an author or editor for following company, with compensation as listed:

  • BMJ, receiving compensation as associate editor.

Dr. Rubin serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Diabetes Association, Communications Director of Health Care Delivery & Quality Improvement Interest Group, without compensation.

Grant funding for staff and salary support, paid to Temple University, from the following non-profit healthcare-related organizations:

  • American Diabetes Association, for the Diabetes INSIDE program, receiving funding for staff.
  • National Institute of Health- National Institute of Diabetes and Digestive and Kidney Diseases, for a K23 award, receiving salary support.

Elizabeth R. Seaquist, MD

Elizabeth R. Seaquist, MDDr. Seaquist is a Professor of Medicine at the University of Minnesota where she holds the Pennock Family Chair in Diabetes Research. She also is the Director of the Division of Endocrinology and Diabetes in the Department of Medicine. She is board certified in Internal Medicine and Endocrinology, Diabetes, and Metabolism.

Dr. Seaquist was the 2014 President, Medicine & Science, of the American Diabetes Association. She is also a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board Exam Committee.

Dr. Seaquist is a clinical investigator interested in the complications of diabetes. Her research focuses on the effect of diabetes on brain metabolism, structure and function. She also directs the University of Minnesota site for the GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) Trials, and has an active clinical practice.

Dr. Seaquist holds a bachelor's degree from Vassar College, Poughkeepsie, New York, and a medical degree from the University of Minnesota in Minneapolis.

As of September 2019, Dr. Seaquist reported the following external relationships:

Funding for clinical trial expenses, staff and salary support paid to the University of Minnesota, from the following companies:

  • Eli Lilly and Company, to assess the cardiovascular safety of dulaglutide.
  • Eli Lilly and Company, for an investigator-initiated trial to examine pharmacokinetics of U-500 insulin.

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Eli Lilly and Company, for reviewing intra nasal glucagon, dulaglutide, receiving reimbursement for travel expenses and honoraria.
  • Six Degrees Medical, member of the International Hypoglycemia Study Group

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

  • WebMD, for a panel discussion on hypoglycemia that was filmed for internet presentation.

Dr. Seaquist serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Diabetes Association, Mentor Advisory Group, Presenter at a Critical Path Innovation Meeting, Participant in Clinical Inertia Meeting, receiving reimbursement for travel expenses.

Grant support with funding for project expenses, staff, and salary support, paid to the University of Minnesota:

  • George Washington University, for a contract to perform GRADE trial funded by the National Institutes of Health.
  • Juvenile Diabetes Research Foundation, for a trial to determine if N-acetyl cysteine (NAC) is an effective and safe therapy for hypoglycemia unawareness in diabetes and for a trial to determine if administration of naloxone curing exercise preserves the counter-regulatory response to hypoglycemia the next day.
  • National Institutes of Health, for a study on brain glucose metabolism.

Savitha Subramanian, MD

Dr. Savitha Subramanian is an associate professor at the University of Washington (UW) Department of Medicine, Division of Metabolism, Endocrinology and Nutrition. She obtained her medical degree from Stanley Medical College in Chennai, India, and completed an internal medical residency at the University of Illinois College of Medicine, Urbana IL. She did an endocrinology fellowship at Washington University in St. Louis and a research fellowship at the University of Washington in Seattle WA. She is board certified in Endocrinology and Metabolism.

Dr. Subramanian is the Medical Director of the UW Lipid Clinic with special expertise in managing individuals with genetic lipid disorders, partial lipodystrophy and complex diabetes. Her research has focused on studying the molecular mechanisms driving inflammation in obese adipose tissue, liver and atherosclerosis. Her other clinical interest includes diabetes management in primary care, having done extensive work as part of a collaborative care model for diabetes working with primary care physicians in the greater Seattle area. She is the physician lead for diabetes population health management for UW Medicine and has developed standardization pathways for outpatient diabetes management for primary care.

Locally, Dr. Subramanian is also involved in many teaching activities for trainees and clinicians. She is the co-chair of the popular Diabetes and Endocrine Update for Primary Care CME courses for the University of Washington. She is a recent past member of the Endocrine Self-Assessment Program workgroup, and is currently part of the Lipid Management Guideline task force of the Endocrine Society.

As of March 2020, Dr. Subramanian reported no ongoing external relationships: